Description

Propafenone HCl USP

Propafenone HCl USP is a high-purity, antiarrhythmic agent used in pharmaceutical formulations to manage cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia. As a class 1C sodium channel blocker, it stabilizes cardiac electrical activity, prolongs conduction, and suppresses abnormal heart rhythms. The hydrochloride salt ensures high solubility, stability, and reproducibility for oral and injectable dosage forms. Propafenone HCl
• Is a USP-compliant antiarrhythmic agent for regulated pharmaceutical use
• Stabilizes cardiac electrical activity and suppresses abnormal heart rhythms
• Is used in oral tablets, capsules, and parenteral formulations for arrhythmia management
• Is suitable for acute and chronic therapy of atrial and ventricular arrhythmias
• Is manufactured under Good Manufacturing Practice (GMP) conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Propafenone HCl is chemically designated as 1-[2-Hydroxy-3-(propylamino)propyl]-3-phenylpropan-1-one hydrochloride. It appears as a white to off-white crystalline powder, freely soluble in water, and stable under controlled storage conditions. Its pharmacological activity is primarily due to sodium channel blockade, with secondary beta-blocking effects contributing to antiarrhythmic efficacy.
In pharmaceutical applications, Propafenone HCl USP is used in:
• Oral tablets and capsules for the long-term management of atrial fibrillation and flutter
• Parenteral formulations for acute treatment of ventricular arrhythmias
• Combination therapies where electrical conduction modulation is required
• Research and clinical studies on arrhythmia treatment and cardiovascular pharmacology
Propafenone HCl demonstrates predictable absorption, distribution, and metabolism, allowing consistent therapeutic effects. Its safety and efficacy profile makes it suitable for both outpatient and inpatient cardiac care settings under physician supervision.
CarboMer supplies Propafenone HCl USP with control over assay, particle size, polymorphic form, residual solvents, and microbial content. Each batch complies with United States Pharmacopeia (USP) standards and is suitable for regulated pharmaceutical use.
The material is packaged in sealed, moisture-protective, tamper-evident containers. Available in laboratory, pilot, and commercial-scale volumes. Minimum order quantities (MOQ), lead times, and documentation including CoA and SDS are provided upon request.
Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), residual solvents, heavy metals, and microbial purity. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer cardiovascular APIs, Propafenone HCl USP is supported by formulation expertise, regulatory guidance, and reliable global supply to enable safe, effective, and compliant pharmaceutical products.